Post-Marketing Surveillance Requirements for Rare Disease Therapies
Post-Marketing Surveillance Requirements for Rare Disease Therapies How to Ensure Safety Monitoring After Rare Disease Drug Approval Introduction: Why Post-Marketing Surveillance Is Critical for Orphan Drugs Approval of rare disease therapies often relies on limited pre-market clinical data, given the constraints of small populations and unmet medical need. This places significant responsibility on post-marketing surveillance…
Read More “Post-Marketing Surveillance Requirements for Rare Disease Therapies” »